Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Schering Pharma reports Nexavar cancer drug trial data

Bayer Schering Pharma reports Nexavar cancer drug trial data

15th June 2010

Bayer Schering Pharma has published new clinical data from a trial evaluating the efficacy of Nexavar, a treatment for advanced non-squamous, non-small cell lung cancer.

The drug was evaluated in combination with the chemotherapeutic agents gemcitabine and cisplatin during the NExUS trial, with results compared to a placebo control group.

It was found that Nexavar did not meet its primary endpoint of improving overall survival in the first-line setting, but a positive secondary endpoint of progression-free survival was observed.

Responding to the data, Dr Dimitris Voliotis, vice-president of global clinical development for oncology at Bayer HealthCare, stated that the firm will continue to evaluate Nexavar in combination with targeted agents, based on positive findings from other studies.

He said: “We are confident with our comprehensive clinical trial program exploring Nexavar’s potential in a variety of tumour types, including lung cancer.”

Earlier this month, the company published data from a 16-year follow-up study of its multiple sclerosis treatment Betaferon, which demonstrated the drug’s long-term effectiveness.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.